C4 Therapeutics Stock Price on August 29, 2024
CCCC Stock | USD 4.00 0.13 3.36% |
Below is the normalized historical share price chart for C4 Therapeutics extending back to October 02, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of C4 Therapeutics stands at 4.00, as last reported on the 26th of December, with the highest price reaching 4.04 and the lowest price hitting 3.76 during the day.
If you're considering investing in CCCC Stock, it is important to understand the factors that can impact its price. C4 Therapeutics retains Efficiency (Sharpe Ratio) of -0.0882, which signifies that the company had a -0.0882% return per unit of price deviation over the last 3 months. C4 Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm C4 Therapeutics' Variance of 27.58, market risk adjusted performance of (0.52), and Information Ratio of (0.11) to double-check the risk estimate we provide.
At present, C4 Therapeutics' Stock Based Compensation To Revenue is projected to increase slightly based on the last few years of reporting. . At present, C4 Therapeutics' Price To Book Ratio is projected to increase based on the last few years of reporting. The current year's Price Fair Value is expected to grow to 1.20, whereas Price To Sales Ratio is forecasted to decline to 12.84. CCCC Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 2nd of October 2020 | 200 Day MA 5.8952 | 50 Day MA 4.99 | Beta 3.056 |
CCCC |
Sharpe Ratio = -0.0882
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | CCCC |
Estimated Market Risk
5.3 actual daily | 47 53% of assets are more volatile |
Expected Return
-0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average C4 Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of C4 Therapeutics by adding C4 Therapeutics to a well-diversified portfolio.
Price Book 1.1258 | Enterprise Value Ebitda (0.42) | Price Sales 8.3865 | Shares Float 54.2 M | Wall Street Target Price 15 |
C4 Therapeutics Main Headline on 29th of August 2024
C4 Therapeutics to Participate in Upcoming September Investo... by finance.yahoo.com
WATERTOWN, Mass., Aug. 29, 2024 -- C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences. Fireside Chat Details Event Wells Fargo Healthcare Conference taking place in Boston, MADateTime September 5, 2024 at 845 AM ET Event 2024 Cantor Global Healthcare Conference taking pl
C4 Therapeutics Valuation on August 29, 2024
It is possible to determine the worth of C4 Therapeutics on a given historical date. On August 29, 2024 CCCC was worth 6.39 at the beginning of the trading date compared to the closed value of 6.43. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of C4 Therapeutics stock. Still, in general, we apply an absolute valuation method to find C4 Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of C4 Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against C4 Therapeutics' related companies.
Open | High | Low | Close | Volume | |
6.37 | 6.44 | 6.15 | 6.37 | 778,837 | |
08/29/2024 | 6.39 | 6.71 | 6.32 | 6.43 | 708,649 |
6.42 | 6.53 | 6.07 | 6.32 | 784,021 |
Backtest C4 Therapeutics | | | C4 Therapeutics History | | | C4 Therapeutics Valuation | Previous | Next |
C4 Therapeutics Trading Date Momentum on August 29, 2024
On August 30 2024 C4 Therapeutics was traded for 6.32 at the closing time. The top price for the day was 6.53 and the lowest listed price was 6.07 . The trading volume for the day was 784 K. The trading history from August 30, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 1.71% . The overall trading delta against the current closing price is 29.08% . |
C4 Therapeutics Fundamentals Correlations and Trends
By evaluating C4 Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among C4 Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. CCCC financial account trend analysis is a perfect complement when working with valuation or volatility modules.About C4 Therapeutics Stock history
C4 Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for CCCC is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in C4 Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing C4 Therapeutics stock prices may prove useful in developing a viable investing in C4 Therapeutics
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 49.6 M | 45 M | |
Net Loss | -115.4 M | -109.6 M |
C4 Therapeutics Quarterly Net Working Capital |
|
C4 Therapeutics Stock Technical Analysis
C4 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
C4 Therapeutics Period Price Range
Low | December 26, 2024
| High |
0.00 | 0.00 |
C4 Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
C4 Therapeutics December 26, 2024 Market Strength
Market strength indicators help investors to evaluate how C4 Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading C4 Therapeutics shares will generate the highest return on investment. By undertsting and applying C4 Therapeutics stock market strength indicators, traders can identify C4 Therapeutics entry and exit signals to maximize returns
C4 Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for C4 Therapeutics' price direction in advance. Along with the technical and fundamental analysis of CCCC Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of CCCC to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | (0.07) | |||
Jensen Alpha | (0.60) | |||
Total Risk Alpha | (0.84) | |||
Treynor Ratio | (0.53) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Transaction History View history of all your transactions and understand their impact on performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |